Sentiment-Signal
24,8
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Of |
Stammdaten
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Unternehmen & Branche
| Name | PUMA BIOTECHNOLOGY, INC. |
|---|---|
| Ticker | PBYI |
| CIK | 0001401667 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 383,2 Mio. USD |
| Beta | 1,18 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 228,371,000 | 31,111,000 | 0.61 | 216,302,000 | 130,340,000 |
| 2025-09-30 | 10-Q | 54,475,000 | 8,844,000 | 0.17 | 202,862,000 | 115,268,000 |
| 2025-06-30 | 10-Q | 52,436,000 | 5,855,000 | 0.12 | 194,916,000 | 104,718,000 |
| 2025-03-31 | 10-Q | 46,007,000 | 2,974,000 | 0.06 | 196,181,000 | 97,108,000 |
| 2024-12-31 | 10-K | 230,468,000 | 30,278,000 | 0.62 | 213,333,000 | 92,125,000 |
| 2024-09-30 | 10-Q | 80,542,000 | 20,317,000 | 0.41 | 220,721,000 | 71,088,000 |
| 2024-06-30 | 10-Q | 47,083,000 | -4,529,000 | -0.09 | 205,002,000 | 48,509,000 |
| 2024-03-31 | 10-Q | 43,766,000 | -4,815,000 | -0.10 | 214,149,000 | 50,982,000 |
| 2023-12-31 | 10-K | 235,637,000 | 21,591,000 | 0.45 | 230,528,000 | 53,442,000 |
| 2023-09-30 | 10-Q | 56,116,000 | 5,796,000 | 0.12 | 203,605,000 | 38,742,000 |
| 2023-06-30 | 10-Q | 54,568,000 | 2,126,000 | 0.05 | 200,494,000 | 30,399,000 |
| 2023-03-31 | 10-Q | 52,775,000 | 1,401,000 | 0.03 | 196,257,000 | 25,847,000 |
| 2022-12-31 | 10-K | 228,031,000 | 2,000 | 0.00 | 222,059,000 | 21,608,000 |
| 2022-09-30 | 10-Q | 57,102,000 | -360,000 | -0.01 | 198,770,000 | 22,155,000 |
| 2022-06-30 | 10-Q | 59,518,000 | 9,371,000 | 0.21 | 193,651,000 | 19,738,000 |
| 2022-03-31 | 10-Q | 45,736,000 | -3,403,000 | -0.08 | 200,685,000 | 7,145,000 |
| 2021-12-31 | 10-K | 253,155,000 | -29,126,000 | -0.72 | 226,585,000 | -2,446,000 |
| 2021-09-30 | 10-Q | 46,245,000 | -44,672,000 | -1.09 | 226,287,000 | -10,922,000 |
| 2021-06-30 | 10-Q | 53,384,000 | -5,106,000 | -0.13 | 259,998,000 | 29,469,000 |
| 2021-03-31 | 10-Q | 98,169,000 | 16,528,000 | 0.40 | 258,659,000 | 16,337,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-07 | HUNT DOUGLAS M | Officer, See Remarks | Open Market Sale | -5,014 | 5.88 | -29,477.31 | -56,2% | |
| 2026-01-07 | NOUGUES MAXIMO F | Officer, Chief Financial Officer | Open Market Sale | -6,405 | 5.88 | -37,655.00 | -71,8% | |
| 2026-01-07 | AUERBACH ALAN H | Director, Officer, 10% Owner, President and CEO | Open Market Sale | -18,012 | 5.88 | -105,892.55 | -201,8% | |
| 2026-01-06 | AUERBACH ALAN H | Director, Officer, 10% Owner, President and CEO | Open Market Sale | -16,938 | 5.84 | -98,985.67 | -188,6% | |
| 2026-01-06 | HUNT DOUGLAS M | Officer, See Remarks | Open Market Sale | -3,973 | 5.84 | -23,218.21 | -44,2% | |
| 2026-01-06 | NOUGUES MAXIMO F | Officer, Chief Financial Officer | Open Market Sale | -4,540 | 5.84 | -26,531.76 | -50,6% | |
| 2025-11-11 | MILLER MICHAEL PATRICK | Director | Open Market Sale | -20,000 | 4.86 | -97,228.00 | -185,3% | |
| 2025-07-18 | Cesano Alessandra | Director | Open Market Sale | -27,000 | 3.37 | -90,909.00 | -173,3% | |
| 2025-07-09 | AUERBACH ALAN H | Director, Officer, 10% Owner, President and CEO | Open Market Sale | -21,580 | 3.54 | -76,285.30 | -145,4% | |
| 2025-07-09 | NOUGUES MAXIMO F | Officer, Chief Financial Officer | Open Market Sale | -3,935 | 3.54 | -13,910.23 | -26,5% | |
| 2025-07-09 | HUNT DOUGLAS M | Officer, See Remarks | Open Market Sale | -3,443 | 3.54 | -12,171.01 | -23,2% | |
| 2025-07-08 | NOUGUES MAXIMO F | Officer, Chief Financial Officer | Open Market Sale | -5,587 | 3.53 | -19,738.87 | -37,6% | |
| 2025-07-08 | AUERBACH ALAN H | Director, Officer, 10% Owner, President and CEO | Open Market Sale | -25,592 | 3.53 | -90,416.54 | -172,3% | |
| 2025-07-08 | HUNT DOUGLAS M | Officer, See Remarks | Open Market Sale | -4,374 | 3.53 | -15,453.34 | -29,5% | |
| 2025-06-13 | Cesano Alessandra | Director | Open Market Sale | -12,150 | 3.40 | -41,310.00 | -78,7% | |
| 2025-06-13 | Senderowicz Adrian | Director | Open Market Sale | -27,000 | 3.40 | -91,800.00 | -175,0% | |
| 2025-06-13 | Stuglik Brian M | Director | Open Market Sale | -8,100 | 3.39 | -27,459.00 | -52,3% | |
| 2025-06-13 | MOYES JAY M | Director | Open Market Sale | -22,000 | 3.40 | -74,800.00 | -142,6% | |
| 2025-06-13 | WILSON TROY EDWARD | Director | Open Market Sale | -10,800 | 3.40 | -36,720.00 | -70,0% | |
| 2025-06-13 | Dorval Allison | Director | Open Market Sale | -11,610 | 3.40 | -39,474.00 | -75,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.